Peer-reviewed veterinary case report
ESM-1 blood test and heart valve disease in dogs
By Hong, Hee-Jeong et al.·Published in BMC veterinary research·2022·Department of Veterinary Clinical Science, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of endothelial cell-specific molecule-1 as a biomarker of glycocalyx damage in canine myxomatous mitral valve disease.
- Species:
- dog
Plain-English summary
A group of 64 dogs with myxomatous mitral valve disease (MMVD), a common heart condition, was studied to see if a specific protein called ESM-1 could indicate heart health. The dogs with more severe MMVD showed higher levels of ESM-1, especially those that sadly passed away. Interestingly, in some dogs, increasing doses of heart medications like pimobendan and furosemide seemed to lower ESM-1 levels. This suggests that ESM-1 might help veterinarians understand how severe the heart disease is and predict outcomes for dogs with MMVD.
People also search for: dog heart disease symptoms · myxomatous mitral valve disease treatment · ESM-1 in dogs · heart medication for dogs · dog heart failure prognosis
Abstract
BACKGROUND: Endothelial cell-specific molecule-1 (ESM-1) has emerged as a potential biomarker for cardiovascular disease in humans. Myxomatous mitral valve disease (MMVD) is the most common heart disease in dogs, and we hypothesized that MMVD causes chronic inflammation that increases susceptibility to endothelial glycocalyx (eGCX) damage. In this study, we measured the concentration of ESM-1 in a group of dogs with MMVD and evaluated factors affecting eGCX damage. RESULTS: Sixty-four dogs (control, n = 6; MMVD, n = 58) were enrolled in this study. There was no significant difference in serum ESM-1 concentrations among the MMVD stages. The serum ESM-1 concentration was significantly higher in the death group than in the alive group in MMVD dogs. (p = 0.006). In five dogs with MMVD, serum ESM-1 concentrations tended to decrease when the cardiac drug (pimobendan, furosemide, and digoxin) dose was increased. CONCLUSIONS: In cases where MMVD progressed to decompensated heart failure with clinical symptoms and resulted in death, the concentration of serum ESM-1 increased significantly. Therefore, ESM-1 could be utilized as a new potential negative prognostic factor in patients with MMVD.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/35790968/